Clinical Trials Logo

Estrogen Receptor Positive clinical trials

View clinical trials related to Estrogen Receptor Positive.

Filter by:

NCT ID: NCT01281163 Terminated - Clinical trials for Stage IV Breast Cancer

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of lapatinib ditosylate and Akt inhibitor MK2206 in treating women with metastatic breast cancer. Lapatinib ditosylate and Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01149356 Terminated - Clinical trials for Stage IV Breast Cancer

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This partially randomized phase I trial is studying the side effects and the best dose of RO4929097 when given together with exemestane and to see how well it works compared to exemestane alone in treating premenopausal and postmenopausal patients with advanced or metastatic breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving exemestane together with RO4929097 may kill more breast cancer cells.